Top 50 Life Science Startup Investors (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
SOSV
VC Fund
|
167 | United States, China, Canada | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | $50k–$5M |
|
SOSV SF & NY (Fka IndieBio)
VC Fund
|
78 | United States, United Kingdom, Canada | Seed, Pre-Seed, Convertible Note | Biotechnology, Health Care, Medical | $50k–$5M |
|
ARCH Venture Partners
VC Fund
|
45 | United States, China, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $9.1M–$230M |
|
Alexandria Venture Investments
VC Fund
|
39 | United States, Canada, France | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $12M–$150M |
|
Alumni Ventures
VC Fund
|
36 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Health Care | $850k–$75M |
|
OrbiMed
VC Fund
|
31 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $9.8M–$160M |
|
Sofinnova Partners
VC Fund
|
29 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$105M |
|
Bpifrance
VC Fund
|
29 | France, United States, Switzerland | Seed, Venture - Series Unknown, Series A | Software, Health Care, Biotechnology | $752k–$34M |
|
8VC
VC Fund
|
27 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Health Care | $2.5M–$181M |
|
Google Ventures
VC Fund
|
27 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1.1M–$121M |
|
Atlas Venture
VC Fund
|
26 | United States, United Kingdom, Canada | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $750k–$115M |
|
Parkwalk Advisors
VC Fund
|
25 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $991k–$44M |
|
RA Capital Management
VC Fund
|
23 | United States, United Kingdom, China | Series B, Post-IPO Equity, Series A | Biotechnology, Health Care, Therapeutics | $20M–$275M |
|
Gaingels
VC Fund
|
23 | United States, Canada, United Kingdom | Seed, Series A, Venture - Series Unknown | Software, Artificial Intelligence, Health Care | $72k–$35M |
|
Northpond Ventures
VC Fund
|
23 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Life Science | $13M–$95M |
|
Third Rock Ventures
VC Fund
|
22 | United States, Japan, Israel | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$190M |
|
Novartis Venture Fund
VC Fund
|
21 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$107M |
|
Liquid 2 Ventures
VC Fund
|
20 | United States, Mexico, Canada | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Information Technology | $125k–$48M |
|
Andreessen Horowitz
VC Fund
|
20 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Artificial Intelligence, Information Technology | $1.5M–$120M |
|
Fifty Years
VC Fund
|
20 | United States, Germany, Canada | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Artificial Intelligence | $572k–$40M |
|
Oxford Science Enterprises
VC Fund
|
20 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Medical | $1.3M–$168M |
|
Antler
VC Fund
|
19 | United States, Singapore, Australia | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $100k–$29M |
|
2048 Ventures
VC Fund
|
18 | United States, Canada, United Kingdom | Pre-Seed, Seed, Series A | Artificial Intelligence, Software, Health Care | $615k–$17M |
|
Lux Capital
VC Fund
|
18 | United States, United Kingdom, Canada | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $1.6M–$150M |
|
SR One
VC Fund
|
18 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6M–$175M |
|
UK Innovation & Science Seed Fund
VC Fund
|
18 | United Kingdom, United States | Seed, Venture - Series Unknown | Biotechnology, Health Care, Medical | $582k–$5.9M |
|
M Ventures
VC Fund
|
17 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
DCVC
VC Fund
|
17 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Machine Learning | $1M–$130M |
|
Khosla Ventures
VC Fund
|
16 | United States, United Kingdom, India | Series A, Seed, Series B | Artificial Intelligence, Software, Health Care | $1.8M–$100M |
|
Versant Ventures
VC Fund
|
16 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $5M–$107M |
|
Felicis
VC Fund
|
16 | United States, Canada, United Kingdom | Series A, Seed, Series B | Software, Artificial Intelligence, SaaS | $1.5M–$76M |
|
Flagship Pioneering
VC Fund
|
16 | United States, Canada, United Kingdom | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $6.6M–$230M |
|
Right Side Capital Management
VC Fund
|
15 | United States, Canada, United Kingdom | Pre-Seed, Convertible Note, Seed | Software, Artificial Intelligence, SaaS | $50k–$1.7M |
|
Catalio Capital Management
VC Fund
|
15 | United States, Israel, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.7M–$208M |
|
General Catalyst
VC Fund
|
15 | United States, India, United Kingdom | Seed, Series A, Series B | Software, Artificial Intelligence, Health Care | $1.6M–$123M |
|
Novo Holdings
VC Fund
|
15 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.5M–$135M |
|
KdT Ventures
VC Fund
|
15 | United States, India, Canada | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $2.6M–$175M |
|
Omega Funds
VC Fund
|
15 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Future Planet Capital
VC Fund
|
15 | United Kingdom, United States, Singapore | Seed, Convertible Note | Biotechnology, Health Care, Software | $670k–$5.1M |
|
F-Prime
VC Fund
|
15 | United States, China, United Kingdom | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $1.6M–$112M |
|
Bossa Invest
VC Fund
|
14 | United States, Brazil, Mexico | Seed, Pre-Seed, Venture - Series Unknown | Software, Information Technology, Financial Services | $49k–$36M |
|
TCA Venture Group
VC Fund
|
14 | United States, Canada, South Africa | Seed, Venture - Series Unknown, Convertible Note | Health Care, Software, Biotechnology | $50k–$8.5M |
|
Syncona Partners LLP
VC Fund
|
14 | United Kingdom, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.9M–$156M |
|
Apple Tree Partners
VC Fund
|
14 | United States, Canada, United Kingdom | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.5M–$100M |
|
Alix Ventures
VC Fund
|
14 | United States | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Life Science | $2M–$70M |
|
Foresite Capital
VC Fund
|
14 | United States, United Kingdom, China | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $17M–$270M |
|
Cormorant Asset Management
VC Fund
|
14 | United States, China, Switzerland | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $16M–$150M |
|
IQ Capital
VC Fund
|
14 | United Kingdom, United States, Germany | Seed, Series A, Venture - Series Unknown | Software, Artificial Intelligence, Machine Learning | $1.3M–$40M |
|
Prox Ventures
VC Fund
|
13 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $2.5M–$28M |
|
Pear VC
VC Fund
|
13 | United States, Brazil, Colombia | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Information Technology | $175k–$40M |
| Access all 7571 investors in Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
SOSV offers pre-seed capital and follow-on financial support to startups focusing on deep technology and scientific innovation. Founders utilize purpose-built laboratory facilities and engineering spaces to accelerate product development and testing. The firm facilitates connections between entrepreneurs and a network of investors through structured matchmaking events and technology summits.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, China, Canada
Investor stats
- Total investments: 3729
- Round size: Seed $150k–$5M; Pre-Seed $50k–$1.6M; Convertible Note $50k–$3.6M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $306M in 2023
Portfolio highlights
- Halla — Halla Intelligence is a digital solution that leverages over 100 billion shopper and product data points to recommend and promote what grocery items.
- Simply Good Jars — Simply Good Jars is a B-Corp company that delivers healthy meals in reusable + returnable packaging through use of smart refrigerated kiosks placed in offices, transit centers, universities and health-systems. Driven by purpose to change that way people think about consumption, SGJ introduces sustainable business practices into their everydayoperations with a zero-waste goal. For every jar returned back to the company for reuse, they will help feed someone in need and ensure that no packaging materials end up in landfills.
- Verdex Technologies — Verdex Technologies is an advanced materials platform technology that uses nanofibers to disrupt industries. Verdex doesn't just compete, it innovates and disrupts.
IndieBio, re-named SOSV SF and SOSV NY in 2026, are two of SOSV’s three deeply resourced facilities for deep tech founders. The third is SOSV's HAX, in Newark, NJ. SOSV is the most active deep tech venture capital firm globally.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 676
- Round size: Seed $250k–$5M; Pre-Seed $50k–$525k; Convertible Note $150k–$950k
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- FluoSphera — Fluosphera better predicts the effects of molecules through animal-free microphysiological systems, helping you to discover more efficient drugs with less adverse side effects.
- Giraffe Bio — Giraffe Bio uses AI and biomolecules to optimize metal extraction, increase yield, and reduce environmental impact. Revolutionizing sustainable mining technology.
- Transition Metal Solutions — Transition harnesses wild microbial communities to recover copper and other critical metals from low-grade mining resources.
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 475
- Round size: Series A $9.1M–$213M; Series B $15M–$230M; Series C $15M–$167M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $3B in 2024
Portfolio highlights
- Oratomic — Oratomic is a Pasadena-based quantum computing company building fault-tolerant quantum computers with neutral atoms.
- Synchron — The endovascular brain computer interface.
- Soufflé Therapeutics — Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Canada, France
Investor stats
- Total investments: 298
- Round size: Series A $12M–$100M; Series B $25M–$150M; Series C $22M–$140M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Leal Therapeutics — Leal Therapeutics develops novel therapeutics for patients.
- BigHat Biosciences — We use machine learning and synthetic biology to design and engineer antibody therapeutics.
- Khartis Therapeutics — Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases.
Access curated startup investment opportunities and diversified venture capital exposure designed for accredited investors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 2705
- Round size: Seed $850k–$9.9M; Series A $3.5M–$32M; Series B $8M–$75M
- Lead/follow: 4% lead, 96% follow
- Last fund: Likely actively investing — fresh fund, raised $90k in 2026
Portfolio highlights
- NextDroid — NextDroid - We're Doing Something Different
- Hello Patient — Healthcare AI that gets your team off the phone & in front of patients
- Alva Energy — Alva Energy is a nuclear solution based firm that aids challenges related to nuclear power offering on time delivery of nuclear megawatts.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 765
- Round size: Series A $9.8M–$116M; Series B $23M–$148M; Series C $19M–$160M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fresh fund, raised $192M in 2026
Portfolio highlights
- CoGenesys — CoGenesys is a biopharmaceutical company focused on the development of peptide- and protein-based medicines. The company develops peptide and protein-based medicines for cancer, cardiovascular, metabolic, infectious, autoimmune, and CNS diseases.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 353
- Round size: Series A $7M–$70M; Series B $10M–$105M; Series C $12M–$100M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fresh fund, raised $755M in 2025
Portfolio highlights
- Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
- HighLife — HighLife is driven by a mission to deliver innovative treatment options to patients suffering from heart valve diseases.
- EnginZyme — Enzymatic chemistry for cleaner ingredients in personal care, food and pharma. Enginzyme's patented EziG platform makes enzymes work at industrial scale.
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 1722
- Round size: Seed $752k–$6.1M; Series A $2.6M–$34M; Venture - Series Unknown $1.1M–$32M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely actively investing — fresh fund, raised $27M in 2025
Portfolio highlights
- Cofarco — Founded in 2009, Cofarco has established itself as a premier insurance brokerage firm dedicated for complex and specialist risks
- Proteor — Proteor offers a complete range of high quality products and services to the O&P world, through more than 60 clinics.
- Advicenne — Specialty pharmaceutical company focused on the development of pediatric friendly therapeutics for the treatment of orphan renal diseases and neurology.
8VC focuses its investment activities on industries such as life sciences, healthcare, logistics, manufacturing, enterprise software, and defense. Its portfolio support model aids founders in scaling transformational technologies intended to create long-term economic and societal value. The firm actively finances breakthroughs ranging from medical innovations and zero-emission transit models to security compliance and infrastructure automation.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 678
- Round size: Seed $2.5M–$13M; Series A $7.7M–$55M; Series B $17M–$181M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fresh fund, raised $45M in 2026
Portfolio highlights
- Harbor — Harbor is a specialized platform designed to provide insurance and risk management for the AI agentic economy. As AI agents increasingly take over autonomous decision-making tasks within enterprise environments, they introduce unique operational, security, and regulatory risks that traditional safety controls are not built to handle.
- Hello Patient — Healthcare AI that gets your team off the phone & in front of patients
- Sirona Medical — Sirona Medical is revolutionizing radiology by delivering a cloud-native platform that unifies the worklist, viewer, reporter, archive, and AI into a single, intuitive workspace. Designed specifically for radiologists, Sirona’s platform simplifies complex workflows, enhances productivity, and empowers practitioners to work as fast as they think.Founded in San Francisco, CA, Sirona combines deep expertise in the practice and business of radiology to create purpose-built solutions that address the evolving needs of the field. By streamlining radiology workflows and integrating cutting-edge AI, Sirona enables radiologists to deliver better, faster, and more efficient care.
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 1517
- Round size: Seed $1.1M–$15M; Series A $6M–$100M; Series B $15M–$121M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- ngmoco — ngmoco ("Next Generation MObile COmpany") is creating and producing games for the iPhone. CEO Neil Young is a former executive from Electronic Arts, where he oversaw the development of several hit titles. Another EA vet and partner at Kleiner Perkins, Bing Gordon, sits on the board. Kleiner is an investor through its iFund.
- Medallion — Provider credentialing and enrollment reimagined. Accelerate time-to-revenue, stay compliant, and scale provider operations, without adding headcount, through automated credentialing and enrollment.
- EveryONE Medicines — EveryONE Medicines develops nucleic acid therapeutics for pathogenic genetic mutation of patients.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 475
- Round size: Seed $750k–$25M; Series A $4M–$75M; Series B $8M–$115M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely actively investing — fresh fund, raised $400M in 2025
Portfolio highlights
- E Ink — E Ink Corp. is a supplier of electronic paper display (EPD) technologies. Products made with E Ink's electronic ink are designed to possess a paper-like high contrast appearance, ultra-low power consumption, and a thin, light form. E Ink's technology is tailored for many consumer and industrial applications including handheld devices, watches, clocks, and public information and promotional signs.
- Songbird — DropCatch.com helps you secure expiring domain names.
- Ethyreal Bio — Ethyreal Bio is an early-stage biotechnology company developing precision, mechanism-driven therapies for thyroid diseases with high unmet medical needs.
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009, anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth. Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 338
- Round size: Seed $991k–$4.9M; Series A $1.6M–$14M; Series B $1.8M–$44M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- K3 Metrology — K3 Metrology is a specialist metrology company commercialising laser‑based 3D coordinate measurement technology developed at the National Physical Laboratory. The company’s platform is designed to provide high‑accuracy, uncertainty‑aware dimensional data in large‑volume industrial environments, supporting inspection and assembly processes inadvanced manufacturing. Its systems integrate into production workflows where traceable measurements are required across complex geometries and large structures. The technology is applied in sectors such as aerospace, defence, and nuclear, where dimensional integrity and process control are critical.
- MoA Technology — We harness the principles of natural selection to accelerate discovery for better, safer herbicides so farmers can continue to feed the world.
- Quantum Motion — Quantum Motion delivers scalable silicon-based quantum computing using standard semiconductor manufacturing technology.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Post-IPO Equity, Series A
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 578
- Round size: Series A $20M–$128M; Series B $27M–$151M; Post-IPO Equity $35M–$275M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fresh fund, raised $120M in 2025
Portfolio highlights
- Serapha Bio —
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
Gaingels is a venture investment syndicate in service of the LGBT+ community and its allies, investing in companies with LGBT+ founders and C-suite leaders at all stages of growth, as well as in more established companies resolved on building more inclusive teams, with a global portfolio of 130+ companies and $70M in deployed investment capital to date. The Gaingels network also actively supports its portfolio in identifying and recruiting diverse talent to their C-suite and board leadership teams and fosters a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 1354
- Round size: Seed $1M–$8.1M; Series A $5M–$35M; Venture - Series Unknown $72k–$13M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely actively investing — fresh fund, raised $140k in 2026
Portfolio highlights
- Allara — Allara is your all-in-one virtual care team for hormonal, metabolic & gynecological conditions such as PCOS and Endometriosis.
- North.cloud — Automate your enterprise-grade cloud finance with zero effort. Our AI reduces your cloud bill by 50% without any risk, contracts, or technical work.
- Uvi — Uvi provides infrastructure that serves as a context and reasoning layer for enterprise AI agents. The platform resolves internal corporate vocabulary, tracks dependencies, and reconstructs the decision-making intent scattered across disparate systems like Jira, GitHub, and Slack. By unifying data fragments into an integrated knowledge network, it enables AI tools to process query objectives accurately while enforcing existing user access permissions at the retrieval stage.
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 152
- Round size: Series A $13M–$65M; Series B $15M–$95M; Series C $23M–$85M
- Lead/follow: 59% lead, 41% follow
Portfolio highlights
- Culture Biosciences — Culture Biosciences provides a platform of cloud-connected bioreactors, software tools, and process development services that support upstream bioprocess development for biotech and biopharma applications. The company’s offerings include remote experiment design, monitoring, and data analysis through an integrated cloud software interface pairedwith single-use bioreactors for microbial fermentation and cell culture experimentation. Its services encompass clone and strain screening, process optimization, characterization, and bioprocess modeling to help scientific teams refine and scale their workflows. Clients access real-time data and analytics to inform decisions and collaborate across teams using the platform’s tools. Culture Biosciences’s technology is used to advance development of therapeutics, synthetic biology products, and related bioprocesses. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
- OMass Therapeutics — OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
- EnPlusOne Biosciences — EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firms progress in life-changing medicines, technologies, and diagnostics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Japan, Israel
Investor stats
- Total investments: 178
- Round size: Series A $19M–$110M; Series B $11M–$190M; Series C $20M–$108M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $1.1B in 2022
Portfolio highlights
- CytomX Therapeutics — CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
- Jounce Therapeutics — Concentra is a biosciences company.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 237
- Round size: Series A $5.1M–$81M; Series B $11M–$107M; Series C $9M–$75M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Visiogen — Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions.The device isdesigned to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.
- Rein Therapeutics — Rein Therapeutics is advancing a novel pipeline of first-in-class medicines to address unmet medical needs in orphan pulmonary and fibrosis indications.
Liquid 2 Ventures is a venture capital firm that invests in early-stage startups, primarily at the pre-seed and seed stages. It provides capital, founder guidance, operational support, and access to a network of entrepreneurs, investors, and industry contacts.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Mexico, Canada
Investor stats
- Total investments: 1249
- Round size: Seed $1.1M–$9.1M; Pre-Seed $125k–$2.7M; Series A $6M–$48M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely actively investing — fresh fund, raised $12M in 2026
Portfolio highlights
- Albedo — Aerial quality imagery - from space.
- Hilt — Govern data movement in real time. Kernel-level telemetry and anomaly detection built for environments where traditional security tools fall short.
- Eden — Eden unifies medical imaging operations with clinical AI: PACS, teleradiology, AI-assisted diagnosis and structured reporting, deployed across 2,600+ imaging departments.
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 2142
- Round size: Seed $1.5M–$16M; Series A $9M–$55M; Series B $17M–$120M
- Lead/follow: 49% lead, 51% follow
- Last fund: Likely actively investing — fresh fund, raised $1.2B in 2026
Portfolio highlights
- Tennr — Tennr is a custom AI assistant that accelerates research, answers complex questions, and generates custom reports.
- Phota Labs — Phota for iOS is coming soon. Phota Studio and the Phota API keep the same person consistent across AI images and video on any model.
- Supersonik — Supersonik provides an AI-powered platform for SaaS companies to offer 24/7 interactive product demos, enabling prospects to explore and personalize demos instantly without scheduling or manual intervention.
WE BACK HEROES using technology to solve the world's biggest problems
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Germany, Canada
Investor stats
- Total investments: 216
- Round size: Seed $2M–$13M; Pre-Seed $572k–$3.3M; Series A $8.5M–$40M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — raised $90M in 2021
Portfolio highlights
- Wafer — Wafer is an AI optimization platform that automatically accelerates AI models by generating efficient custom GPU kernels.
- Adaption Labs — Adaption is building adaptive intelligence that continually learns. Efficient, evolving AI for any industry or language.
- Multiply Labs — Multiply Labs develops robotic systems that manufacture small-batch drugs. Current pharma production methods are manual, slow, and costly. We believe that the only way to scale them is with cloud-controlled robots.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking on challenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 210
- Round size: Seed $1.3M–$12M; Series A $6.3M–$45M; Series B $9.1M–$168M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $299M in 2022
Portfolio highlights
- Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
- OMass Therapeutics — OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: United States, Singapore, Australia
Investor stats
- Total investments: 2387
- Round size: Seed $158k–$4.6M; Pre-Seed $100k–$600k; Series A $4.1M–$29M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely actively investing — fresh fund, raised $7.5M in 2026
Portfolio highlights
- iiba — Iiba is a geospatial platform that specializes in providing location information related to child-rearing.
- Obud — Obud is a wellness reservation systems that is designed for holistic health and lifestyle management purposes. The company's systems offer a comprehensive suite of tools for booking wellness activities, managing schedules, and accessing curated wellness programs, enabling wellness centers to streamline their operations, enhance userengagement, and promote a balanced and healthy lifestyle.
- Plouton AI —
We back visionary founders who are building technologies of the future. 2048 Ventures is a thesis-driven earliest stage venture capital firm. We are founders, experienced operators, nerds and dreamers obsessed with the future. We've backed over 200 startups and have the experience and conviction to lead your pre-seed or seed round. We get you and your vision before others. We are systems thinkers, engineers, and product junkies. We think about the future non-stop and are ready to understand and back you before anyone else. When we decide to invest, we write you a check and then help you close the rest of the round. We lead rounds with high conviction, and write $500K - $2M checks.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Pre-Seed, Seed, Series A
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 216
- Round size: Seed $1.5M–$6.5M; Pre-Seed $615k–$2.7M; Series A $8M–$17M
- Lead/follow: 67% lead, 33% follow
- Last fund: Likely actively investing — fresh fund, raised $82M in 2026
Portfolio highlights
- Zeroset — Zeroset is an applied artificial intelligence research company that develops AI technologies and software products. The company conducts research in AI systems and builds tools for autonomous agents, including memory management infrastructure. It develops AI software designed to support agent performance and long-term information retention.
- Aslan Protects — America's adversaries faded into a digital domain that humans alone could never follow. Aslan builds what can.
- TwoStep Therapeutics — TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.
Lux Capital focuses on sectors such as artificial intelligence, biotechnology, advanced materials, space, and energy, backing businesses that apply scientific research to commercial applications. It provides capital alongside strategic input on product development, company building, and long-term positioning. The firm works with technical founders and research-driven teams to translate complex innovations into scalable businesses. It evaluates opportunities based on the underlying science, potential for industry impact, and feasibility of execution over extended time horizons.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 706
- Round size: Seed $1.6M–$25M; Series A $7M–$90M; Series B $13M–$150M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely actively investing — fresh fund, raised $10M in 2026
Portfolio highlights
- Adimab — Premier Human Antibody Discovery and Optimization
- Modal Labs — Modal develops machine learning software to help run code in the cloud. The software enables users to run or deploy machine learning models, massively parallel compute jobs, task queues, web apps, and more. It also writes the code to launch hundreds of custom containers and runs scripts in the cloud faster than on the local machine.
- Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 203
- Round size: Series A $6M–$100M; Series B $15M–$114M; Series C $22M–$175M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely actively investing — fresh fund, raised $237M in 2025
Portfolio highlights
- CalciMedica — CalciMedica is a clinical-stage biopharmaceutical company advancing CRAC channel inhibitors for pulmonary hypertension and acute pancreatitis.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Korsana Biosciences — Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications.
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Venture - Series Unknown
- Geography: United Kingdom, United States
Investor stats
- Total investments: 151
- Round size: Seed $582k–$5.9M; Venture - Series Unknown $1M–$4.8M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- StandardX — StandardX is a deep-tech company building the isotope refinery powered by a scalable, compact particle accelerator platform.
- SILVIA BIO — SilVia Bio develops technologies to analyze and optimize mammalian cell factories used in biomanufacturing. The company focuses on identifying critical parameters that limit bioproduction yield and product quality in cell systems such as CHO and HEK cells. Its platform provides cell profiling services that generate interpretable data on manufacturing-relevant bottlenecks. Based on these insights, SilVia Bio designs and supplies precision media additives formulated to address specific rate-limiting cellular processes. The offerings are intended for biopharmaceutical and biomanufacturing teams seeking to improve titre, cell performance, and consistency in production processes. SilVia Bio also collaborates with industrial partners to apply its platform within real manufacturing environments.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 189
- Round size: Seed $2.4M–$24M; Series A $5.8M–$56M; Series B $13M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Mueon — semiconductor-based systems for AI and hyperscale computing
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
We are deep tech venture capital.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 518
- Round size: Seed $1M–$9.1M; Series A $6M–$50M; Series B $15M–$130M
- Lead/follow: 23% lead, 77% follow
- Last fund: Likely actively investing — fresh fund, raised $5M in 2026
Portfolio highlights
- CH4 Global — CH4 Global is an aquaculture solutions provider dedicated to urgently impacting climate change at scale. Lead by a world-class team of senior business builders, scientists and entrepreneurs, the company is initially leveraging proven science and technology for growing seaweed into innovative new livestock supplement that reduces methane produced bycows by up to 90%. Among early investors are a select group of prominent family offices and private investors. CH4 Global have also received non-dilutive capital support from government organizations from around the world. CH4 Global is a Delaware corporation based in Henderson, NV.
- TypeSafe AI — TypeSafe AI develops artificial intelligence models and software tools designed to support automated decision-making within applications and business workflows. Its primary product, Jev, is a System One Model that processes structured questions and returns typed decisions accompanied by probability scores and confidence estimates. These outputs help software systems perform tasks such as classification, scoring, routing, content evaluation, and customer service operations. TypeSafe AI provides an application programming interface and a web-based console that enable developers and organizations to integrate Jev into their existing systems. Its technology uses a training approach called Reinforcement Learning for Calibrated Decisions, which focuses on producing decisions that software can interpret and apply directly. The platform also supports configurable confidence thresholds, allowing applications to automate actions when confidence meets defined criteria or direct uncertain cases for human review. Through these capabilities, TypeSafe AI focuses on making AI-driven decisions usable in structured, programmatic workflows.
- Universal Quantum — Universal Quantum is building quantum computers to tackle real-world problems that would take today’s fastest supercomputers billions of years to solve.
Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech, offering strategic support to help build long-lasting companies.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Series A, Seed, Series B
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 1508
- Round size: Seed $1.8M–$23M; Series A $5.5M–$47M; Series B $11M–$100M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely actively investing — fresh fund, raised $31M in 2026
Portfolio highlights
- Phia — Build your closet seamlessly, and find the best prices instantly.
- Synchron — The endovascular brain computer interface.
- LanzaTech — LanzaTech offers a technology platform that transforms industrial waste gases such as carbon monoxide and carbon dioxide into valuable chemical intermediates and fuels through microbial gas fermentation. The company’s process captures emissions from heavy-industry sources and uses specialized microbes to convert those gases into ethanol, which is then refined into materials such as monoethylene glycol for packaging, solvents, proteins, and sustainable aviation fuels. LanzaTech integrates its bioconversion system with industrial emitters, enabling the reuse of carbon streams that would otherwise be released into the atmosphere, and supplies downstream manufacturers in sectors including packaging, textiles, and aviation with fossil-alternative feedstocks.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 333
- Round size: Series A $5M–$78M; Series B $12M–$105M; Series C $12M–$107M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely still investing — raised $5M in 2024
Portfolio highlights
- Inari Medical — Inari Medical is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. They are focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. It hasdeveloped two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for thrombectomy in the peripheral vessels and is used to treat patients suffering from deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.The company was founded in 2011 and is headquartered in Irvine, California.
- Gate Bioscience — Gate Bioscience is developing Molecular Gates, a new frontier in protein elimination. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin, inside cells, and prevent them from emerging to cause disease.
- Dayra Therapeutics — Dayra Therapeutics manufactures peptide based medicines.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Backing founders building iconic companies that transcend boundaries
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Series A, Seed, Series B
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 710
- Round size: Seed $1.5M–$14M; Series A $4.4M–$42M; Series B $10M–$76M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely actively investing — fresh fund, raised $900M in 2025
Portfolio highlights
- Arena — Moved to @arena
- Sooth Labs —
- Solcoa Industries — Solcoa Industries develops carbon-zero rare earth metals for critical supply chain needs and promote sustainable industrial practices
We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 257
- Round size: Series A $6.6M–$75M; Series B $11M–$230M; Series C $12M–$123M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $2.6B in 2024
Portfolio highlights
- ZoomInfo — ZoomInfo is the #1 GTM Platform: Marketing and sales AI plus the best B2B data. All-in-one lead generation, prospecting, market intelligence , and ABM software.
- iris labs — Iris Labs is an AI company focused on improving human wellbeing through personalized AI experiences for self-awareness, and personal growth.
- Serif Biomedicines — Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies.
Systematic Pre-Seed Startup Capital
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Pre-Seed, Convertible Note, Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 2078
- Round size: Seed $50k–$1.7M; Pre-Seed $50k–$450k; Convertible Note $50k–$400k
- Lead/follow: 3% lead, 97% follow
- Last fund: Likely actively investing — fresh fund, raised $55M in 2025
Portfolio highlights
- tbh — tbh is a developer of a mobile application designed to provide anonymous feedback to friends. The company's mobile application facilitates asking or answering questions, open text fields and invite abuse when combined with anonymity, enabling users to say things without repercussions and feel better about themselves from the positive feedbackon social networks.
- Athel AI — Athel AI provides an AI-powered clinical intake platform for physicians and healthcare teams. Its tools conduct patient interviews through voice, chat, and video, capture clinical histories, and generate structured summaries for physicians. The platform also supports AI-assisted reception, dictation, multilingual interviews, and automated clinical workflows. Athel AI provides clinical decision support while keeping diagnosis and treatment decisions under the physician's authority.
- Vidrovr — Vidrovr develops multimodal computer vision and machine learning systems to index, tag, and understand video. It processes videos with specific domain constraints, such as in sports, government, and media verticals. Its technology enables its users to search an indexed video corpus and retrieve content inside videos and link it to other media likephotos and text.The company Integrates social media to enable direct interactions between multimedia content. Vidrovr was founded in 2016 and is headquartered in New York.
Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, Switzerland
Investor stats
- Total investments: 151
- Round size: Series A $9.7M–$150M; Series B $26M–$130M; Series C $70M–$208M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fresh fund, raised $16M in 2026
Portfolio highlights
- OSPRI — OSPRI is updating the infectious illness testing plan. Established by the combination of Community Direct DX, Scienetix, and the R&D section of Advanta Genetics, OSPRI is among the first molecular testing platforms in the world to be entirely vertically integrated.
- BigHat Biosciences — We use machine learning and synthetic biology to design and engineer antibody therapeutics.
- Enveda Biosciences — Enveda exists to give hope to millions of people around the world by accelerating the discovery of better medicines.
Investing in powerful, positive change that endures
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 2301
- Round size: Seed $1.6M–$18M; Series A $6.7M–$75M; Series B $14M–$123M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely actively investing — fund raised in 2026
Portfolio highlights
- Lemonade — Lemonade operates as a full-stack insurance company powered by AI and behavioral economics and driven by social good. It is a licensed insurance carrier, offering homeowners and renters insurance. Lemonade replaces brokers and bureaucracy with bots and machine learning, delivering zero paperwork and instant everything. The company uses artificialintelligence and behavioral economics to set rates for the homes and renters it insures. Lemonade was founded in Tel Aviv, Israel, in 2015 and is headquartered in New York, NY, United States.
- Datalogix — Datalogix® is the industry-recognized leader at connecting digital media and offline purchasing data. We help more than half of the top 100 consumer marketers increase the effectiveness and measurability of their advertising. DLX Platform®, encompasses over $1 trillion in consumer spending and powers campaigns for more than 75% of online mediacompanies. DLX ROI® is rapidly becoming the industry standard for measuring offline sales lift for digital media. Datalogix also offers predictive analytics for Direct Mail, and integrated media solutions via the DLX Net. Our expertise spans the major consumer segments, including Retail, CPG, Automotive, Telecom, Travel and Financial Services. We are based in Colorado, with offices in New York City, San Francisco, Boston, Chicago, Detroit, and London.
- Legora — By streamlining and simplifying legal workflows, we empower elite law firms and legal professionals to work more efficiently and effectively. Enabling them to focus on higher-value tasks and deliver exceptional results for their clients.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 409
- Round size: Series A $9.5M–$133M; Series B $15M–$135M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
KdT Ventures is the standard for early-stage frontier science investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, India, Canada
Investor stats
- Total investments: 96
- Round size: Seed $2.6M–$13M; Series A $9M–$70M; Series B $25M–$175M
- Lead/follow: 9% lead, 91% follow
- Last fund: Likely actively investing — fresh fund, raised $4.9M in 2026
Portfolio highlights
- Zag Bio — Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
- Skeletalis — Skeletalis is a biotechnology startup focused on developing next-generation precision medicines for musculoskeletal diseases, primarily osteoporosis.
- Tacit Therapeutics — Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 172
- Round size: Series A $16M–$200M; Series B $38M–$165M; Series C $14M–$208M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $470M in 2023
Portfolio highlights
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- Anaconda BioMed — Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note
- Geography: United Kingdom, United States, Singapore
Investor stats
- Total investments: 288
- Round size: Seed $670k–$5.1M
- Lead/follow: 5% lead, 95% follow
- Last fund: Likely still investing — raised $23M in 2022
Portfolio highlights
- Unloq AI — Unloq is a Decision Intelligence Platform that turns your company data and live market signals into governed strategic recommendations. Approved, tracked, measured.
- Nourished — At Nourished we create innovative. personalised nutrition stacks that are truly unique to you. Vegan, waste-free and always made to order.
- K3 Metrology — K3 Metrology is a specialist metrology company commercialising laser‑based 3D coordinate measurement technology developed at the National Physical Laboratory. The company’s platform is designed to provide high‑accuracy, uncertainty‑aware dimensional data in large‑volume industrial environments, supporting inspection and assembly processes inadvanced manufacturing. Its systems integrate into production workflows where traceable measurements are required across complex geometries and large structures. The technology is applied in sectors such as aerospace, defence, and nuclear, where dimensional integrity and process control are critical.
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 547
- Round size: Seed $1.6M–$20M; Series A $8M–$87M; Series B $15M–$112M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Innovent Biologics — Innovent Biologics, Inc. is a privately held biopharmaceutical company that is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by the venture arm of Fidelity, which is a major investment firm in the US, Lilly Ventures, and Suzhou bioBay. Theregistered capital is 30Million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.
- Mersana Therapeutics — Discover how Day One is disrupting the status quo of traditional drug development to bring new medicines to children and adults with cancer.
- PlasmaGen Biosciences — PlasmaGen BioSciences is an Indian Bio-pharmaceutical organization specializing exclusively in Plasma Protein Therapy.Headquartered in Bangalore- India, PlasmaGen has been making every effort in the domain of Plasma product Industry and has become an Imperative one stop destination for the medical fraternity for most of the plasma products need.They have a basket of plasma products and the widest range of immunoglobulins in India catering to the requisites of various realms viz. Haematology, Oncology, Immunology, Paediatrics, Rheumatology, Dermatology and Neurology.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Aprenda a Investir em Startups
Show more...Investment focus
- Industry: Software, Information Technology, Financial Services
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: United States, Brazil, Mexico
Investor stats
- Total investments: 2097
- Round size: Seed $166k–$5.8M; Pre-Seed $49k–$2M; Venture - Series Unknown $632k–$36M
- Lead/follow: 3% lead, 97% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- FFID — FFID develops AI chatbot platform automating customer communication, lead generation, and marketing workflows.
- SprayX — Company specialized in interactive process control to evaluate and guarantee the quality of agricultural spraying with excellence. Empowers, leads and monitors applicators in Application Technology tasks.
- Sandwiche — Sandwiche creates customizable link in bio pages enabling social media monetization and affiliate marketing management.
TCA Venture Group is the largest angel investor group in the United States, possessing more than 300 members in five networks in Los Angeles, Orange County, San Diego, Central Coast, and the Inland Empire. Its members provide funding and guidance to more early-stage, high-growth companies in Southern California than any other investment group. Members invest in companies in a wide range of industries, including the life sciences, biotech, IT, services, retail, Internet, financial, software, media, consumer products, and tech startups. TCA as a whole gives companies more than just capital; they also provide counsel, mentoring, and access to an extensive network of potential investors, customers, strategic partners, and management talent. Tech Coast Angels has been ranked by CB Insights to be among the Top 20 Angel Groups in the US; TCA was also ranked as #1 for Network Centrality, meaning we have more connections than anyone! If you are in the game-changing business, we are here to help.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Seed, Venture - Series Unknown, Convertible Note
- Geography: United States, Canada, South Africa
Investor stats
- Total investments: 395
- Round size: Seed $525k–$3.8M; Convertible Note $50k–$4.5M; Venture - Series Unknown $400k–$8.5M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- EdgeX — Edokonta builds software that allows hospitals to track mobile equipment, such as IV pumps and ultrasounds. The company was founded in 2018 and based in San Diego, California.
- Nested Knowledge — Nested Knowledge is designing an interface that allows you to examine the data from a comprehensive literature review on research questions of interest. The interactive, nested features facilitate therapeutic comparisons, assist with research organization, and allow physicians to compare nuances across patient characteristics and outcomes.
- Major Medical Devices — Major Medical Devices develops next-generation vascular devices for endovascular repair and related surgical procedures.
Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 78
- Round size: Seed $1.9M–$17M; Series A $13M–$87M; Series B $29M–$156M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- OMass Therapeutics — OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
- Re-Aim Therapeutics — Re‑Aim Therapeutics is a UK‑based biotech start‑up developing functional cures for T cell–mediated autoimmune diseases by selectively depleting pathogenic T‑cell subsets. Its lead asset, REA‑001, is a monoclonal antibody designed to potently and precisely eliminate disease‑causing type‑17 T cells, aiming to reset the immune system and achievedurable, treatment‑free remission in multiple autoimmune conditions.
ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategic insight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 100
- Round size: Seed $3.5M–$8M; Series A $15M–$75M; Series B $29M–$100M
- Lead/follow: 63% lead, 37% follow
- Last fund: May invest from a new fund soon — raised $1B in 2020
Portfolio highlights
- Ascidian Therapeutics — Ascidian Therapeutics is a biotechnology company intended for medical use in medical and clinical gene therapy.
- Red Queen Therapeutics — Staying ahead of viral threats with new innovations in antiviral therapy
- Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.
Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....
Show more...Investment focus
- Industry: Health Care, Biotechnology, Life Science
- Stage:Seed, Series A, Pre-Seed
- Geography: United States
Investor stats
- Total investments: 24
- Round size: Seed $2M–$12M; Pre-Seed $2.7M–$2.7M; Series A $12M–$70M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- iOrganBio — iOrganBio is a pioneering cell production platform that uses CellForge to facilitate the intelligent manufacturing of human cells and organoids.
- Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
- Italic Health — Italic Health, Inc. is a healthcare technology company building a unified platform for managing patient data, medical billing, and insurance workflows. Its software integrates health records, appointment scheduling, and AI-driven analytics to improve care coordination, financial processes, and patient engagement.
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 225
- Round size: Series A $17M–$165M; Series B $24M–$140M; Series C $37M–$270M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $900M in 2024
Portfolio highlights
- Thyme Care — Thyme Care is a dedicated team of nurses and care experts offering value-based cancer care to help you through all phases of the cancer experience.
- Korsana Biosciences — Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications.
- Khartis Therapeutics — Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases.
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, China, Switzerland
Investor stats
- Total investments: 254
- Round size: Series A $16M–$102M; Series B $27M–$150M; Series C $30M–$146M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely actively investing — fresh fund, raised $75M in 2025
Portfolio highlights
- Epicrispr Biotechnologies — The Gene Expression Modulation System (GEMS) technology from Epic-Bio combines a DNA-binding protein, a tailored guide RNA, and any of a wide range of modulator proteins to generate a powerful new type of genetic medicine. GEMS medicines have the ability to precisely modify gene expression both in and out of the body. They are mutation-independent,which means that a single GEMS design can address the majority or all genetic subtypes of a disease.
- Processa Pharmaceuticals — Processa Pharmaceuticals is committed to developing drug products aimed at improving the quality of life for patients with unmet medical needs.
- Cue Biopharma — A precision immuno-engineering company targeting transformative therapies for patients with significant unmet needs across allergic and autoimmune diseases.
IQ Capital is a dedicated European deep tech venture capital firm, built on the conviction that frontier technology will underpin the next generation of globally significant companies. We back founders leveraging scientific breakthroughs to build enduring global businesses. We have invested in over 100 of Europe's most ambitious deep tech teams across six funds since 2005.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 215
- Round size: Seed $1.3M–$13M; Series A $4.7M–$40M; Venture - Series Unknown $1.4M–$30M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Mindgard — Mindgard is the leading provider of AI Red Teaming solutions.
- Imperagen — Imperagen is a biotechnology research company focused on enzyme engineering, artificial intelligence, and synthetic biology.
- Undecimal Bio — Undecimal Bio operates as a platform biotechnology company that develops targeted delivery mechanisms for small interfering RNA (siRNA) therapeutics. The company utilizes a proprietary platform that combines combinatorial chemistry libraries with transformer-based artificial intelligence to discover molecular conjugates capable of guiding genetic medicines to specified cells outside of the liver. This approach aims to circumvent traditional delivery constraints to expand the reach of RNA therapeutics into a broader range of therapeutic areas and human organs.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 81
- Round size: Seed $2.5M–$14M; Series A $2.8M–$28M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Shengxin Medical — Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Pear VC partners with entrepreneurs from day zero to build category-defining companies.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Brazil, Colombia
Investor stats
- Total investments: 528
- Round size: Seed $1.6M–$9M; Pre-Seed $175k–$3.5M; Series A $8.5M–$40M
- Lead/follow: 19% lead, 81% follow
- Last fund: Likely still investing — raised $3.4M in 2024
Portfolio highlights
- Presonance — Presonance provides brain-based creative testing for agencies and research partners. Its platform simulates audience responses to videos, images, and scripts to assess how creative content may influence viewer behavior. Users can analyze audience responses moment by moment and use the results to evaluate and refine campaigns before launch. Presonance also provides sample analyses and research-backed insights for creative testing.
- Phinity Labs — Phinity Labs builds AI systems designed to fully automate the entire silicon microchip engineering process, spanning from original architectural concepts to final manufacturing preparation.
- Hertha Metals — At Hertha Metals, we are developing advanced steel solutions to accelerate the growth and global competitiveness of the U.S. steel industry.
Life Science Investor funding at a glance
Stats across 7.9k deals from 7.6k investors.
Access all 7571 investors in Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 7571 investors investing in Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!